fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

Abstract Background The safety, tolerability, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% (dual-vial unit of human immunoglobulin 10% and recombinant human hyaluronidase [rHuPH20]) were assessed in children with primary immunodeficiency diseases (PIDs). Me...

Full description

Bibliographic Details
Main Authors: Peter Čižnár, Marion Roderick, Helen Schneiderova, Miloš Jeseňák, Gergely Kriván, Nicholas Brodszki, Stephen Jolles, Charles Atisso, Katharina Fielhauer, Shumyla Saeed-Khawaja, Barbara McCoy, Leman Yel
Format: Article
Language:English
Published: BMC 2024-09-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Hyaluronidase
Immunoglobulins
Inborn errors of immunity (IEI)
Primary immunodeficiency diseases
Patient safety
Pediatrics
Online Access:https://doi.org/10.1186/s13223-024-00904-9

Internet

https://doi.org/10.1186/s13223-024-00904-9

Similar Items